Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Retained Earnings (2022 - 2025)

Stoke Therapeutics has reported Retained Earnings over the past 4 years, most recently at $543000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $543000.0 for Q4 2025, up 459.6% from a year ago — trailing twelve months through Dec 2025 was $543000.0 (up 459.6% YoY), and the annual figure for FY2025 was $543000.0, up 459.6%.
  • Retained Earnings for Q4 2025 was $543000.0 at Stoke Therapeutics, up from -$439.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for STOK hit a ceiling of $543000.0 in Q4 2025 and a floor of -$480.3 million in Q3 2024.
  • Median Retained Earnings over the past 4 years was -$123.5 million (2022), compared with a mean of -$195.6 million.
  • Peak annual rise in Retained Earnings hit 459.6% in 2025, while the deepest fall reached 2676126.67% in 2025.
  • Stoke Therapeutics' Retained Earnings stood at -$1.2 million in 2022, then tumbled by 34099.91% to -$401.8 million in 2023, then surged by 99.96% to -$151000.0 in 2024, then skyrocketed by 459.6% to $543000.0 in 2025.
  • The last three reported values for Retained Earnings were $543000.0 (Q4 2025), -$439.8 million (Q3 2025), and -$401.4 million (Q2 2025) per Business Quant data.